1 B ), where greater ctDNA reductions were consistently associated with lower HRs and highly significant p values, suggesting that even modest declines in ctDNA could have clinical relevance.
← all excerpts
Evaluating Circulating Tumor DNA Clearance as an Early Intermediate End Point Predicting Clinical Benefit in Metastatic Nonsquamous NSCLC After First-Line Chemoimmunotherapy.
1
—
—